Literature DB >> 229187

In vitro induction of T-lymphocyte-mediated cytotoxicity by infectious murine type C oncornaviruses.

T Taniyama, H T Holden.   

Abstract

We have developed a system to induce oncornavirus-specific secondary cytotoxic response in vitro. When Moloney strain of murine sarcoma virus-immune spleen cells were cultivated with purified infectious Moloney murine leukemia virus (M-MuLV) or with supernates of tissue culture cells containing infectious virus, a virus-specific secondary cytotoxic response directed against type-specific determinant(s) of M-MuLV was generated in vitro, as determined by a 4-h 51Cr-release assay. The effector cells were susceptible to the treatment with anti-Thyl.2 plus complement, but were unrelated to natural killer cells (NK), because they could not lyse some target cells specific for M-MuLV in both the induction phase and the interaction between effector cells and target cells. Furthermore, a product of the env gene of M-MuLV, perhaps gp70, appeared to be responsible for this response, because viruses with recombinations in the env gene between ecotropic M-MuLV and a xenotropic virus failed to induce a response. When infectious M-MuLV was exposed to UV-light at different doses, the ability of UV-treated M-MuLV to induce a secondary cytotoxic response decreased in parallel with infectivity, indicating that infectivity was necessary for the induction of this response.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 229187      PMCID: PMC2185727          DOI: 10.1084/jem.150.6.1367

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  39 in total

1.  Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a murine xenotropic C type virus.

Authors:  P J Fischinger; A E Frankel; J H Elder; R A Lerner; J N Ihle; D P Bolognesi
Journal:  Virology       Date:  1978-10-15       Impact factor: 3.616

2.  Friend strain of spleen focus-forming virus is a recombinant between ecotropic murine type C virus and the env gene region of xenotropic type C virus.

Authors:  D H Troxler; D Lowy; R Howk; H Young; E M Scolnick
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

3.  Antigenic specificities of the cellular immune response of C57BL/6 mice to the Moloney leukemia/sarcoma virus complex.

Authors:  L Enjuanes; J C Lee; J N Ihle
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

Review 4.  The murine sarcoma virus-induced tumor: exception or general model in tumor immunology?

Authors:  J P Levy; J C Leclerc
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

5.  Studies on the nature of the cell surface antigen reacting with cytolytic T lymphocytes in murine oncornavirus-induced tumors.

Authors:  E Gomard; J P Levy; F Plata; Y Henin; V Duprez; A Bismuth; T Reme
Journal:  Eur J Immunol       Date:  1978-04       Impact factor: 5.532

6.  Immunofluorescent analysis of expression of the RNA tumor virus major glycoprotein, gp71, on surfaces of virus-producing murine and other mammalian species cell lines.

Authors:  M W Cloyd; D P Bolognesi; D D Bigner
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

7.  Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells.

Authors:  T J Braciale; K L Yap
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

8.  The induction of virus-specific cytotoxic T lymphocytes with solubilized viral and membrane proteins.

Authors:  R Finberg; M Mescher; S J Burakoff
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

9.  Joint recognition by cytotoxic T cells of inactivated Sendai virus and products of the major histocompatibility complex.

Authors:  J W Schrader; G M Edelman
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

10.  Involvement of fusion activity of ultraviolet light-inactivated Sendai virus in formation of target antigens recognized by cytotoxic T cells.

Authors:  K Sugamura; K Shimizu; F H Bach
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  7 in total

1.  Cytolytic T lymphocyte response to Moloney sarcoma virus.

Authors:  V Duprez; S J Burakoff
Journal:  Surv Immunol Res       Date:  1983

2.  Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection.

Authors:  H Shida; T Tochikura; T Sato; T Konno; K Hirayoshi; M Seki; Y Ito; M Hatanaka; Y Hinuma; M Sugimoto
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

3.  Cell surface antigens of murine leukemias induced by radiation leukemia virus. Recognition of individually distinct cell surface antigens by cytotoxic T cells on leukemias expressing crossreactive transplantation antigens.

Authors:  H Morishita; H Shiku; K Horibe; Y Obata; E Stockert; H F Oettgen; L J Old; K Yamada
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

4.  Cell surface antigens of radiation leukemia virus-induced BALB/c leukemias defined by syngeneic cytotoxic T lymphocytes.

Authors:  Y Kaneko; H F Oettgen; Y Obata; E Nakayama
Journal:  Jpn J Cancer Res       Date:  1989-03

5.  Antigenic specificity of the cytolytic T lymphocyte response to murine sarcoma virus-induced tumors. III. Characterization of cytolytic T lymphocyte clones specific for Moloney leukemia virus-associated cell surface antigens.

Authors:  A Weiss; K T Brunner; H R MacDonald; J C Cerottini
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

Review 6.  Characterization of gP85gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo.

Authors:  F A van der Hoorn; T Lahaye; V Müller; M A Ogle; H D Engers
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

7.  Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus.

Authors:  S Mitsunaga; H Kimura; Y Yamaguchi; A Mikata
Journal:  Jpn J Cancer Res       Date:  1988-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.